14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
KURA vs CRMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CRMD Overall Winner
6-Pillar Tally: KURA 1 – 5 CRMD
Matrix Metrics: KURA 4 – 6 CRMD
As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Kura Oncology, Inc. (KURA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). KURA carries a Unified Composite Score of 64.1/100 (BUY) at $7.30 (N/M Forward P/E, -394.3% operating margin), whereas CRMD carries 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin).
Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (64.1/100 BUY vs. CRMD 53.2/100 HOLD), CRMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (41.0% vs. -394.3% operating margin) and revenue trajectory (-47.7% vs. +10.1% YoY).
Technical & Structure Timing Caution: KURA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KURA Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $690.9M market capitalization and -394.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
CRMD Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $384.7M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment46.4% of Rev ($488M)
90D Engineering Disclosures0 Published
Investor FAQ KURA vs CRMD Key Questions & Quantitative Answers
As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Kura Oncology, Inc. (KURA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). KURA carries a Unified Composite Score of 64.1/100 (BUY) at $7.30 (N/M Forward P/E, -394.3% operating margin), whereas CRMD carries 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin). Composite vs. Pillar Nuance: While KURA currently prints a higher short-term Unified Composite Score (64.1/100 BUY vs. CRMD 53.2/100 HOLD), CRMD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (41.0% vs. -394.3% operating margin) and revenue trajectory (-47.7% vs. +10.1% YoY). Technical & Structure Timing Caution: KURA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.8); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KURA leads the Growth & Scale pillar: KURA posts +10.1% YoY revenue growth and +0.0% YoY earnings growth on $79M TTM revenue (N/A gross margin, -394.3% operating margin), compared with CRMD at -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), KURA cumulative revenue shifted +40.0% while CRMD shifted +675.0%. In operating R&D and SG&A reinvestment, KURA deploys N/A (0 90-day corporate R&D disclosures) versus 46.4% of Rev ($488M) (0 disclosures) for CRMD.
CRMD screens cheaper on headline valuation multiples. KURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.3x EV/Revenue (-112.4% FCF margin), whereas CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KURA (-224.8% ROE) versus CRMD (15.3% ROE) capital efficiency.
In options market volatility and institutional positioning, KURA carries 103.8% implied volatility (20th %ile, Compressed (<25th %ile)), a 1.50x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 108% Vol realized risk). By comparison, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.